Synergy Pharmaceuticals Inc fka SGYPQ

[Snackman]

Synergy Pharma (SGYP): Conference Datapoints Point To Increased Physician Engagement - Oppenheimer

Oppenheimer analyst, Derek Archila, reiterated his Outperform rating on shares of Synergy Pharmaceuticals (NASDAQ: SGYP) after hosting a management dinner and the company demonstrated an an impressive presence at the Digestive Disease Week conference where it highlighted the recent launch of Trulance (chronic idiopathic constipation) which they think brought significant awareness for the drug among SGYP's target physicians.

Physician checks at the conference indicated that some have started writing for Trulance and cited their need to gain more experience with the drug. Importantly, physicians were very enthusiastic about Trulance's dosing flexibility which has been core to the analyst's thesis.

Maintains Outperform rating, price target goes to $9 (from $10).

For an analyst ratings summary and ratings history on Synergy Pharmaceuticals click here. For more ratings news on Synergy Pharmaceuticals click here.

Shares of Synergy Pharmaceuticals closed at $4.14 yesterday.

https://www.streetinsider.com/Analyst+Comments/Synergy+Pharma+%28SGYP%29%3A+Conference+Datapoints+Point+To+Increased+Physician+Engagement+-+Oppenheimer/12890576.html